➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Medtronic
McKinsey
Harvard Business School
AstraZeneca

Last Updated: September 19, 2021

DrugPatentWatch Database Preview

WEGOVY Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Wegovy, and what generic alternatives are available?

Wegovy is a drug marketed by Novo and is included in one NDA. There are four patents protecting this drug.

This drug has eighty patent family members in thirty countries.

The generic ingredient in WEGOVY is semaglutide. Three suppliers are listed for this compound. Additional details are available on the semaglutide profile page.

DrugPatentWatch® Generic Entry Outlook for Wegovy

Wegovy will be eligible for patent challenges on December 5, 2021. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 29, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for WEGOVY
International Patents:80
US Patents:4
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Formulation / Manufacturing:see details
Drug Prices: Drug price information for WEGOVY
What excipients (inactive ingredients) are in WEGOVY?WEGOVY excipients list
DailyMed Link:WEGOVY at DailyMed
Drug patent expirations by year for WEGOVY
Drug Prices for WEGOVY

See drug prices for WEGOVY

DrugPatentWatch® Estimated Generic Entry Opportunity Date for WEGOVY
Generic Entry Date for WEGOVY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for WEGOVY

US Patents and Regulatory Information for WEGOVY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo WEGOVY semaglutide SOLUTION;SUBCUTANEOUS 215256-005 Jun 4, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
Novo WEGOVY semaglutide SOLUTION;SUBCUTANEOUS 215256-005 Jun 4, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Novo WEGOVY semaglutide SOLUTION;SUBCUTANEOUS 215256-001 Jun 4, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Novo WEGOVY semaglutide SOLUTION;SUBCUTANEOUS 215256-003 Jun 4, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Novo WEGOVY semaglutide SOLUTION;SUBCUTANEOUS 215256-004 Jun 4, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Novo WEGOVY semaglutide SOLUTION;SUBCUTANEOUS 215256-002 Jun 4, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Novo WEGOVY semaglutide SOLUTION;SUBCUTANEOUS 215256-001 Jun 4, 2021 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for WEGOVY

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1863839 C01863839/01 Switzerland ⤷  Try it Free PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66604 02.07.2018
1863839 2018C/016 Belgium ⤷  Try it Free PRODUCT NAME: OZEMPIC - SEMAGLUTIDE; AUTHORISATION NUMBER AND DATE: EU/1/17/1251 20180212
1863839 22/2018 Austria ⤷  Try it Free PRODUCT NAME: SEMAGLUTID; REGISTRATION NO/DATE: EU/1/17/1251 20180212
1863839 132018000000262 Italy ⤷  Try it Free PRODUCT NAME: SEMAGLUTIDE(OZEMPIC); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1251, 20180212
1863839 1890018-3 Sweden ⤷  Try it Free PRODUCT NAME: SEMAGLUTIDE; REG. NO/DATE: EU/1/17/1251 20180212
1863839 300936 Netherlands ⤷  Try it Free PRODUCT NAME: SEMAGLUTIDE; REGISTRATION NO/DATE: EU/1/17/1251 20180208
1863839 122018000075 Germany ⤷  Try it Free PRODUCT NAME: OZEMPIC-SEMAGLUTID; REGISTRATION NO/DATE: EU/1/17/1251 20180208
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Medtronic
McKinsey
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.